Modified And Stabilized Gdf Propeptides And Uses Thereof

Abstract

Modified and stabilized propeptides of Growth Differentiation Factor proteins, such as GDF-8 and Bone Morphogenetic Protein-11, are disclosed. Also disclosed are methods for making and using the modified propeptides to prevent or treat human or animal disorders in which an increase in muscle tissue would be therapeutically beneficial. Such disorders include muscle or neuromuscular disorders (such as amyotrophic lateral sclerosis, muscular dystrophy, muscle atrophy, congestive obstructive pulmonary disease, muscle wasting syndrome, sarcopenia, or cachexia), metabolic diseases or disorders (such as type 2 diabetes, noninsulin-dependent diabetes mellitus, hyperglycemia, or obesity), adipose tissue disorders (such as obesity), and bone degenerative diseases (such as osteoporosis).


Claims
Owners (US)

Information currently unavailable.

IPC Classifications
Download PDF
Document Preview
Document History
  • Publication: Jul 14, 2009
  • Application: Dec 21, 2006
    US US 61459406 A
  • Priority: Dec 21, 2006
    US US 61459406 A
  • Priority: Feb 8, 2002
    US US 7149902 A
  • Priority: Feb 8, 2001
    US US 26750901 P

Download Citation


Sign in to the Lens

Feedback